Incretin-based Therapy in Late Preclinical Type 1 Diabetes

Inclusion Criteria: * 10-30 years of age * positive for at least 2 islet autoantibodies * glucose intolerance or dysglycemia: impaired glucose tolerance (IGT, 2-hour p-gluc 7.8-11.0mmol/l), or impaired fasting glucose (IFG, fp-gluc 6.1-6.9mmol/l), and/or 10% rise in HbA1c since the last measurement (2 - 12 mo ago), and/or p-gluc at least 11.1mmol/l at 30, 60 or 90 min during OGTT * not pregnant Exclusion Criteria: * allergic to liraglutide or other ingredients of Victoza * type 1 diabetes * diabetic ketoacidosis * previous treatment in the last three months with any antidiabetic medication * impaired liver or kidney function or on dialysis * severe heart failure * severe stomach or gut problem resulting in gastroparesis, or inflammatory bowel disease * past or current history of pancreatitis * serum calcitonin value above normal (\>50 ng/l or at least 3.4pmol/l) * presence of any chronic metabolic, hematologic or malignant disease * obesity BMI at least 30 * pregnant females and females of childbearing potential who are not using adequate contraceptive methods. * breast-feeding